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Abstract
This study aimed to determine the serum levels of free L-carnitine, acetyl-L-carnitine and 34
acyl-L-carnitine in healthy subjects and in patients with or at risk of Alzheimer’s disease.
Twenty-nine patients with probable Alzheimer’s disease, 18 with mild cognitive impairment
of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were
enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tan-
demmass spectrometry. The concentrations of acetyl-L-carnitine progressively decreased
passing from healthy subjects group (mean±SD, 5.6±1.3 μmol/L) to subjective memory
complaint (4.3±0.9 μmol/L), mild cognitive impairment (4.0±0.53 μmol/L), up to Alzheimer’s
disease (3.5±0.6 μmol/L) group (p<0.001). The differences were significant for the compari-
sons: healthy subjects vs. subjective memory complaint, mild cognitive impairment or Alz-
heimer’s disease group; and subjective memory complaint vs. Alzheimer’s disease group.
Other acyl-carnitines, such as malonyl-, 3-hydroxyisovaleryl-, hexenoyl-, decanoyl-, dode-
canoyl-, dodecenoyl-, myristoyl-, tetradecenoyl-, hexadecenoyl-, stearoyl-, oleyl- and lino-
leyl-L-carnitine, showed a similar decreasing trend, passing from healthy subjects to
patients at risk of or with Alzheimer’s disease. These results suggest that serum acetyl-L-
carnitine and other acyl-L-carnitine levels decrease along the continuum from healthy sub-
jects to subjective memory complaint and mild cognitive impairment subjects, up to patients
with Alzheimer’s disease, and that the metabolism of some acyl-carnitines is finely con-
nected among them. These findings also suggest that the serum levels of acetyl-L-carnitine
and other acyl-L-carnitines could help to identify the patients before the phenotype conver-
sion to Alzheimer’s disease and the patients who would benefit from the treatment with ace-
tyl-L-carnitine. However, further validation on a larger number of samples in a longitudinal
study is needed before application to clinical practice.
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Introduction
Among the major challenges of modern research there are the treatment and prevention of
Alzheimer's disease (AD), the most common and fearsome form of dementia. Researches,
focusing on the characterization of the earliest, preclinical stages of dementia, identified transi-
tional states between normal aging and AD, known as mild cognitive impairment (MCI) and
subjective memory complaint (SMC). MCI refers to the clinical condition in which persons
experience memory loss and/or other cognitive impairments greater than expected for age and
level of education, but they do not fulfill accepted criteria for dementia. This condition is at
high risk for developing AD and is suitable for possible therapeutic intervention [1, 2]. The
term subjective memory complaint (SMC) is generally used to indicate a report of memory
problems without pathological results on neuropsychological tests, which may or may not be
perceived by others. However, there is no consensus on a standard definition for this symptom.
There is growing evidence that SMC in the elderly, without organic or identifiable condition
known to cause memory disturbance, is associated with an increased risk of cognitive decline
and dementia [3, 4]. Some studies have shown structural, functional, and metabolic neuroim-
aging changes in SMC that closely resemble those seen in AD [5–7]. The subjects with MCI
and/or SMC therefore should be identified and possibly treated to prevent the progression to
dementia.
Acetyl-L-carnitine (ALC) is an endogenous molecule that is synthesized in the mitochon-
dria by acetylation of L-carnitine. Approximately, the adult brain contains 80% of FC, 10–15%
of ALC, and less than 10% long chain acyl-carnitines [8]. ALC has many different functions in
the body and its supplementation has shown beneficial effects in the treatment of AD, produc-
ing a slower progression of mental deterioration [9–11]. However, larger multicenter, random-
ized controlled trial found no significant effect on cognitive decline [12, 13]. The authors of a
recent meta-analysis [14] concluded that there is no sufficient evidence to recommend the rou-
tine use of ALC in clinical practice and that more studies, particularly on pharmacokinetics of
ALC, are needed [14]. Although many studies have investigated the neurobiological properties
of ALC and its supplementation effects in several neurological diseases including AD, the con-
centration of endogenous ALC and other acyl-carnitines in subjects with different severity of
cognitive disturbances has yet to be fully investigated.
Aim of this study was to determine the endogenous levels of ALC and other acyl-L-carnitines
in different groups of subjects along the continuum from normal to SMC, MCI, up to AD, and
verify if such metabolites could be used as potential serum biomarkers of AD progression.
Materials and Methods
Study population
One hundred and seventeen participants were consecutively recruited from the Centre for
Research and Training inMedicine for Aging (CeRMA), University of Molise. They were divided
into four groups based on their clinical profiles: 29 participants with probable AD (7 males,
22 females, mean age±SD: 71.4±9.5 years), 18 with amnestic MCI (4 males, 14 females, mean
age±SD: 69.4±8.2 years), 24 with SMC (8 males, 16 females, mean age±SD: 66.0±7.6 years) and
46 HS (20 males, 26 females, mean age±SD: 65.0±7.1 years). The characteristics of participants
are summarized in Table 1. The body mass index (BMI) of AD patients was slightly lower
than in other groups (Table 1), but the differences were not significant (F = 2.250; df = 3, 113;
p = 0.086). The Mini Nutritional Assessment (MNA) [15] showed that all participants were well-
nourished (MNA score> 23.5), with the exception of 11 AD patients who were at risk of malnu-
trition (MNA score between 18 and 23), but not malnourished.
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Patients with probable AD were diagnosed according to National Institute of Neurological
and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Associa-
tion (NINCDS-ADRDA) criteria [16] and presented Mini Mental State Examination (MMSE)
score<24 [17] and Clinical Dementia Rating (CDR) score>0.5 [18]. Subjects with amnestic
MCI met the Petersen’s diagnostic criteria [1], had MMSE24 and CDR = 0.5, and showed
memory impairment as assessed via age-sex-education-adjusted scores on at least one of the
following tests: Rey's word list immediate and delayed recall [19] and Prose memory, immedi-
ate and delayed [20]. Participants with SMC stated that their memory function has deteriorated
compared to earlier stages in life, reported that the time of onset was in adulthood, had a score
of 25 or more on the Memory Complaint Questionnaire (MAC-Q) [21] and showed normal
objective memory performance on Rey's and Prose memory tests [3]. To summarize, MCI sub-
jects showed both subjective and objective memory impairment, SMC participants presented
only memory complaints with a normal score on the memory tests and HS showed neither sub-
jective nor objective memory impairment. Depression at screening was assessed with the Geri-
atric Depression Scale (GDS) [22], and participants with a GDS score of 6 or more were
considered depressed and excluded from the study. The patients on treatment with cerebro-
active drugs underwent a wash-out period of at least 14 days before assessment. This study was
Table 1. Demographic and clinical characteristics of study groups.
Group
AD (n. 29) MCI (n. 18) SMC (n. 24) HC (n. 46)
Age (mean+SD, y) 71.4+9.5 69.4+8.2 66.0+7.6 65.0+7.1
Male (n, %) 7 (5.9%) 4 (3.4%) 8 (6.8%) 20 (17.1%)
Female (n, %) 22 (18.8%) 14 (11.9%) 16(13.7%) 26 (22.2%)
Education level (mean+SD, y) 8.9+4.9 9.3+4.1 11.8+3.0 12.4+3.3
BMI (mean+SD, kg/m2) 25.8+5.4 27.78+3.6 27.52+4.1 28.56+4.1
MMSE (mean+SD, score) 12.6+8.0 26.7+2.2 29.6+0.7 29.6+0.7
Smokea (n, %) 8; 27.6% 5; 27.7% 5; 20.8% 12; 26.1%
Dyslipidemia (n, %) 10; 34.5% 5; 27.8% 6; 25.0% 12; 26.1%
Diabetes (n, %) 7; 24.1% 4; 22.2% 4; 16.7% 6; 13.0%
Hypertension (n, %) 14; 48.3% 9; 50.0% 10; 41.7% 18; 39.1%
Arrhythmia (n, %) 2; 6.9% 2; 11.1% 2; 8.3% 3; 6.5%
Heart failureb (n, %) 2; 6.9% - - 2; 4.3%
TIA/Stroke (n, %) 2; 6.9% 1; 5.5% 2; 8.3% 1; 2.2%
Chronic kidney diseasec (n, %) 1; 3.4% - - -
Prior Tumors (n, %) 3; 10.3% 1; 5.5% 3; 12.5% 5; 10.9%
Antihypertensive (n, %) 14; 48.3% 9; 50.0% 10; 41.7% 18; 39.1%
Lipid-lowering (n, %) 5; 17.2% 5; 27.8% 6; 25.0% 9; 19.6%
Hypoglycemic (n, %) 7; 24.1% 4; 22.2% 4; 16.7% 6; 13.0%
Antiacid (n, %) 8; 27.6% 3; 16.7% 6; 25.0% 8; 17.4%
Antiplatelet (n, %) 7; 24.1% 2; 11.1% 5; 20.8% 7; 12.2%
Supplements (n, %) 5; 17.2% 3; 16.7% 5; 20.8% 6; 13.0%
a, current or former smoker
b, subjects in NYHA (New York Heart Association) class I-II
c, subjects with glomerular filtration rate (GFR)>30 mL/min/1.73 m2
-, none; AD, Alzheimer disease; MCI, mild cognitive impairment; SMC, subjective memory complaint; HS, healthy subjects; BMI, Body mass index;
MMSE, Mini Mental State Examination; TIA, transient ischemic attack.
doi:10.1371/journal.pone.0155694.t001
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conducted in accordance with ethical principles stated in the Declaration of Helsinki, as well as
with approved national and international guidelines for human research. The Ethics Commit-
tee of University of Molise reviewed and approved this study, and subjects or caregivers were
completely informed of the study procedures and provided written informed consent.
Blood collection and biomarker analyses
Blood collection was done between 8:00 and 8:30 AM after an overnight fasting of at least 8–10
hours. Venous blood was collected into vacutainer serum tubes (Becton & Dickinson, Milan,
Italy) and centrifuged within four hours. All serum samples were stored at -80°C until the prep-
aration of spots and shipment to the analytical laboratory. To prepare spot serum from
patients, 20 μl of each serum were spotted on filter paper (Whatman, 903, Gmbh, Dassel Ger-
many), dried, and sent by courier to the laboratory at room temperature. The analytical labora-
tory was blinded to sample identification codes. Sample preparation from serum, preparation
of internal quality controls and metabolite analyses were performed according to the conven-
tional validated method as previously reported [23–25].
Briefly, labeled standards of acyl-carnitines were purchased from Cambridge Isotope Labo-
ratories (Andover, MA, USA); a stock solution was made in methanol, and the standard con-
centrations were in the range 7.6–152 mmol/L for acyl-carnitines. In order to obtain working
solutions, daily dilutions (1:100) were made using methanol. All chemicals and solvents were
of the highest purity available from commercial sources, and were used without any further
purification. To prepare serum calibrators, different amounts of acyl-carnitines standard solu-
tion were spiked into drug-free serum samples. Twenty μl of each spiked serum were spotted
on filter paper (Whatman, 903, Gmbh, Dassel Germany) and let to dry. The dried serum spot
was automatically punched (a disk of 3.2 mm of ; contains about 2 μL of serum) into a 1.5-mL
tube, and 200 μL of methanol containing labeled standards were added. The sample was shaken
on a vortex system for 20 min, thereafter was dried under a nitrogen flow at 50°C. The
extracted acyl-carnitines were re-suspended using 200 μL of water/acetonitrile (1:1) containing
0.1% formic acid, and 40 μL of sample solution were injected using the flow injection analysis
(FIA) mode into the mass spectrometer.
Targeted analysis of FC and acyl-carnitines was performed by tandem mass spectrometry
(MS/MS). Samples were delivered directly into the TurbolonSpray ionization source of an API
4000 (SCIEX, Toronto, Canada) instrument. Labeled internal standards of FC and acyl-carni-
tines were purchased from Cambridge Isotope Laboratories (Andover, MA, USA); a stock solu-
tion was made in methanol. The standard concentrations were in the range of 7.6–152 μmol/L
for FC and acyl-carnitines, the daily working solution was made by dilution of the stock solu-
tion (1:200) using methanol–water 90:10 v/v. The analytes concentrations were calculated
automatically using the Chemoview software (SCIEX, Toronto, Canada). The ionization source
operated under positive ion mode at a voltage of 5500 volts and with a turbo gas flow of 10 L/
min of air, heated to 450°C (nominal heating-gun temperature). Mass calibration and resolu-
tion adjustments on the resolving quadrupoles were performed automatically using a PPG 2 x
10−6 mol/L solution introduced via the built-in infusion pump. Mass resolution was set on
both quadrupoles at 0.7 amu at half height of mass-peak for all MS and MS/MS experiments.
Collision-activated dissociation MS/MS was performed through the LINAC Q2 collision cell,
operating with 10 mTor pressure of nitrogen as collision gas. Declustering potential, collision
exit potential and collision energy were automatically optimized for FC and acyl-carnitines by
the "quantitation optimization" option. The resulting declustering potential was +50V, optimal
collision energy and collision exit potential were set at 26V and 20V, respectively. The targeted
metabolite profiling was focused on the estimation of free L-carnitine (FC or C0), acetyl-L-
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carnitine (ALC or C2); propionyl-L-carnitine (C3); acrylyl-L-carnitine (C3:1); malonyl-L-
carnitine (C3-DC); butyryl-L-carnitine (C4); methylmalonyl-L-carnitine (C4-DC); 3-hydroxy-
butyryl-L-carnitine (C4-OH); isovaleryl-L-carnitine (C5); glutaryl-L-carnitine (C5-DC);
3-hydroxyisovaleryl-L-carnitine (C5-OH); tiglyl-L-carnitine (C5:1); hexanoyl-L-carnitine
(C6); hexenoyl-L-carnitine (C6:1); adipyl-L-carnitine (C6-DC); octanoyl-L-carnitine (C8);
octenoyl-L-carnitine (C8:1); decanoyl-L-carnitine (C10); decenoyl-L-carnitine (C10:1);
3-hydroxydecanoyl-L-carnitine (C10-OH); dodecanoyl-L-carnitine (C12); dodecenoyl-L-
carnitine (C12:1); 3-hydroxydodecanoyl-L-carnitine (C12-OH); myristoyl-L-carnitine (C14);
tetradecenoyl-L-carnitine (C14:1); tetradecadienoyl-L-carnitine (C14:2); 3-hydroxytetradaca-
noyl-L-carnitine (C14-OH); palmitoyl-L-carnitine (C16); hexadecenoyl-L-carnitine(C16:1);
3-hydroxyhexadecanoyl-L-carnitine (C16-OH); 3-hydroxyhexadecenoyl-L-carnitine
(C16:1-OH); stearoyl-L-carnitine (C18); oleyl-L-carnitine (C18:1); linoleyl-L-carnitine
(C18:2); 3-hydroxyoctadecanoyl-L-carnitine (C18-OH); 3-hydroxyoctadecenoyl-L-carnitine
(C18:1-OH).
Analytical variability (CV%) was estimated during the analysis of samples on three different
levels (μmol/L) of quality controls of free L-carnitine and acyl-L-carnitines (S1 Table). In addi-
tion, we calculated 19 molar ratios as additional markers: C2/C0, C3/C0, C3/C4, C5/C3, C5/
C4, C5/C8, C3/C16, C5DC/C4, C5DC/C8, C5DC/C12, C8/C6, C8/C6, C8/C10, C14:1/C16:1,
C14:1/C5, C14:1/C4, C14:1/C8, C14/C14:1, C0/(C16+C18), (C16+C18:1)/C2.
Statistical analysis
Data were analyzed using the SPSS (v. 17.0) statistical software package (SPSS Inc., Chicago,
USA). Variables were examined for outliers and extreme values by means of box and normal
quantile-quantile plots, and Shapiro-Wilk’s and Kolmogorov-Smirnov’s tests. When normal dis-
tribution could not be accepted, variable transformations (square, square root, logarithmic, recip-
rocal of square root or reciprocal transformations) were reviewed. The reciprocal of square root
of FC, C2, C4-OH, C5, C5-DC, C5-OH, C8, C10, C10:1, C10-OH, C12, C12:1, C16, and C18:1,
the logarithm of C3, C3:1, C3-DC, C4, C4-DC, C6-DC, C12-OH, C14, C14:1, C14:2, C14-OH,
C18:2 and C18-OH and, finally, the natural logarithm of C6 and C6:1 concentrations helped to
improve the distribution shape. Group differences (HS vs. SMC vs. MCI vs. AD) were evaluated
by one-way multivariate analysis of variance (MANOVA) with age, gender, education level and
body mass index (BMI) as covariates. The assumption of equality of variance was assessed by
means of Levene's test. Finally, post-hoc pairwise multiple comparison using Bonferroni's correc-
tion was performed in order to detect significant differences among mean groups.
Multivariate statistical analysis was also performed using projection methods as imple-
mented in MetaboAnalyst 2.0 on-line package [26, 27]. Principal component analysis (PCA)
was first applied to detect sample metabolites trends and clusterings in an unsupervised man-
ner, and the partial least-squares discriminant analysis (PLS-DA) was applied to reinforce clas-
sification and to better identify clusterings. The concentrations of all variables analyzed were
preprocessed by normalization by the sum, transformed by Log normalization, and with
mean-centered and auto-scaling before to built the model. The model quality was evaluated by
the goodness-of-fit parameter (R2) and the goodness-of-prediction parameter (Q2). The classi-
fication performance of selected metabolites was assessed using the receiver operating charac-
teristic (ROC) curve and the area under the curve (AUC).
Results
MANOVA, including age, gender, education level and BMI as covariates, showed a statistically
significant differences between groups (F = 2.005; df = 105, 231; p<0.001; Pillai's
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Trace = 1.430; partial η2 = 0.477). The results of univariate ANOVA and post hoc multiple
comparisons are reported in Table 2. Endogenous concentrations of ALC progressively
decreased from HS (mean±SD, 5.547±1.308 μmol/L) to SMC (4.343±0.869 μmol/L), from
SMC to MCI (4.013±0.526 μmol/L) and fromMCI to AD (3.529±0.639 μmol/L) group
[F = 24.589; df = 3, 109; p<0.001; partial η2 = 0.404] (Table 2). Pairwise multiple comparisons
showed that HS was significantly different from SMC (p<0.005), MCI (p<0.005) and AD
(p<0.005) group, and this latter was significantly different from SMC (p<0.005) group. The
comparisons SMC vs. MCI (p = 1.000) and AD vs. MCI (p = 0.082) were not significant
(Table 2). Other acyl-carnitines, such as C3-DC, C5-OH, C6:1, C10, C12, C12:1, C14, C14:1,
C16:1, C18, C18:1 and C18:2 showed a similar behavior, decreasing from HS through SMC
and MCI up to AD patients (Table 2). However, while the comparison HS vs. AD was signifi-
cant for all such acyl-carnitines, the comparison MCI vs. HS was also significant for C10,
C12:1, C14:1, C16:1, C18 and C18:1, and the comparison HS vs. SMC for C16:1 and C18. For
the acyl-carnitines C3, C8 and C10:1, only the comparison HS vs. MCI was significant. FC did
not show significant differences between groups (Table 2).
The projections of PCA are reported in S1A Fig. The first three principal components,
obtained from the original data set, explained the 62% of data variance. The PCA score in the
new coordinate system allowed a good separation of AD samples from samples of the other
subjects (MCI, SMC and HS). PLS-DA (S1B Fig) showed a better separation between AD and
HS, while both MCI and SMC classes clustered very closed and in an intermediate zone. The
first two components of PLS-DA explained the 52% of the model, and both MCI and SMC
were distributed between AD patients and HS (Fig 1A). The Fig 1B shows a 3D score plot of
PLS-DA, in which the combination of the first three components clearly separated AD samples
(red) from HS (light blue), while MCI (blue) and SMC (green) clustered in an intermediate
zone.
The panel A of S2 Fig shows the first three latent variables of PLS-DA used to build the
model: the prediction accuracy (Accuracy) based on cross-validation, the sum of squares cap-
tured by the model (R2), and the cross-validated R2 (Q2). The optimal number of components
(n = 3) was determined by Q2 (). To avoid the propensity of PLS-DA to data overfitting, a per-
mutation test was performed to detect it. The panel B of S2 Fig shows the result of permutation
test, which randomly reassigned the class labels and performed PLS-DA on the newly relabeled
data set. The process was repeated thousand time, and the test was statistically significant
(p<0.001, less than 1/1,000).
The 12 metabolites (C2, C12, C3DC, C16:1, C14:0, C12:1, C5-OH, C18:1, C18:0, C3, C6:1
and C18:2) and the 3 molar ratios (C2/C0, C3/C4 and C3/C0), identified by PLS-DA as VIP
(variable importance in projection) with a score>1.3, are reported in Fig 2. Fig 3 reports the
box-plots of 12 acyl-carnitines classified as VIP from PLS-DA.ROC analysis showed that C2,
C12, C18:1 and C18:2, identified as significant features by both PLS-DA and ANOVA, yielded
an AUC ranging from 0.82 (C2) to 0.72 (C12 and C18:1) (Fig 4).
Discussion
To the best of our knowledge, this research is the first to investigate the serum levels of endoge-
nous acyl-carnitines in different groups of subjects along the continuum from normal to AD,
including subjects with SMC. Our results show a progressive decrease of ALC and other acyl-
carnitine serum levels passing from HS through SMC and MCI up to AD groups (Table 2).
Post hoc pairwise comparisons showed that 3 acyl-carnitines (C2, C16:1 and C18) significantly
decreased in AD, MCI and SMC, 4 acyl-carnitines (C10, C12:1, C14:1 and C18:1) in AD and
MCI, and 6 (C3-DC, C5-OH, C6:1, C12, C14 and C18:2) only in AD, compared to HS. Three
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Table 2. Serum levels (μmol/L) of free L-carnitine and acyl-carnitines in the four studied groups.
Metabolites Group* ANOVA Significant pairwise comparisons
AD MCI SMC HS F (3,
109)
p
value
Free L-carnitine (C0) 28.302
(5.911)
27.974
(5.226)
26.969
(4.141)
28.923
(6.301)
0.387 0.763 n.a.
Acetyl- (C2) 3.529
(0.639)
4.013
(0.526)
4.343
(0.869)
5.547
(1.308)
24.589 <0.001 AD vs SMC; AD vs HS; MCI vs HS;
SMC vs HS
Propionyl- (C3) 0.182
(0.076)
0.149
(0.052)
0.175
(0.048)
0.215
(0.075)
4.187 0.008 MCI vs HS
Acrylyl- (C3:1) 0.016
(0.009)
0.017
(0.007)
0.015
(0.006)
0.013
(0.005)
0.931 0.428 n.a.
Malonyl- (C3-DC) 0.026
(0.007)
0.028
(0.009)
0.032
(0.012)
0.036
(0.014)
4.823 0.003 AD vs HS
Butyryl- (C4) 0.169
(0.097)
0.182
(0.219)
0.144
(0.052)
0.156
(0.076)
0.160 0.923 n.a.
Methylmalonyl- (C4-DC) 0.039
(0.015)
0.038
(0.011)
0.035
(0.012)
0.040
(0.015)
0.814 0.489 n.a.
3-hydroxybutyryl- (C4-OH) 0.025
(0.008)
0.026
(0.007)
0.023
(0.008)
0.027
(0.009)
2.584 0.057 n.a.
Isovaleryl- (C5) 0.071
(0.031)
0.075
(0.023)
0.073
(0.022)
0.082
(0.028)
1.409 0.244 n.a.
Glutaryl- (C5-DC) 0.032
(0.012)
0.029
(0.008)
0.040
(0.017)
0.040
(0.016)
3.117 0.029 n.s.
3-hydroxyisovaleryl- (C5-OH) 0.037
(0.010)
0.043
(0.010)
0.041
(0.010)
0.045
(0.011)
3.217 0.026 AD vs HS
Tiglyl- (C5:1) 0.033
(0.006)
0.033
(0.009)
0.036
(0.009)
0.034
(0.008)
0.868 0.460 n.a.
Hexanoyl- (C6) 0.042
(0.017)
0.038
(0.009)
0.036
(0.011)
0.047
(0.036)
1.289 0.282 n.a.
Hexenoyl- (C6:1) 0.066
(0.014)
0.069
(0.015)
0.072
(0.020)
0.081
(0.018)
3.776 0.013 AD vs HS
Adipyl- (C6-DC) 0.035
(0.014)
0.035
(0.013)
0.034
(0.009)
0.034
(0.012)
0.004 1.000 n.a.
Octanoyl- (C8) 0.126
(0.047)
0.115
(0.034)
0.135
(0.047)
0.160
(0.133)
3.177 0.027 MCI vs HS
Octenoyl- (C8:1) 0.063
(0.019)
0.065
(0.020)
0.069
(0.022)
0.070
(0.024)
0.696 0.557 n.a.
Decanoyl- (C10) 0.117
(0.079)
0.104
(0.043)
0.136
(0.080)
0.161
(0.159)
5.694 0.001 AD vs HS; MCI vs HS
Decenoyl- (C10:1) 0.079
(0.041)
0.063
(0.019)
0.079
(0.034)
0.089
(0.047)
3.643 0.015 MCI vs HS
3-hydroxydecanoyl- (C10-OH) 0.032
(0.012)
0.029
(0.008)
0.040
(0.017)
0.040
(0.016)
3.117 0.029 n.s.
Dodecanoyl- (C12) 0.043
(0.020)
0.052
(0.023)
0.054
(0.021)
0.072
(0.064)
7.322 <0.001 AD vs SMC; AD vs HS
Dodecenoyl- (C12:1) 0.046
(0.022)
0.044
(0.018)
0.052
(0.017)
0.061
(0.019)
7.297 <0.001 AD vs HS; MCI vs HS
3-hydroxydodecanoyl- (C12-OH) 0.015
(0.005)
0.014
(0.006)
0.016
(0.007)
0.017
(0.006)
1.480 0.224 n.a.
Myristoyl- (C14) 0.029
(0.011)
0.033
(0.008)
0.031
(0.009)
0.039
(0.016)
4.293 0.007 AD vs HS
Tetradecenoyl- (C14:1) 0.045
(0.025)
0.041
(0.015)
0.048
(0.022)
0.056
(0.026)
4.169 0.008 AD vs HS; MCI vs HS
(Continued)
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acyl-carnitines (C3, C8 and C10:1) were significantly reduced in MCI compared to HS
(Table 2). In particular, ALC significantly decreased on average by 21% in SMC, 27% in MCI
and 36% in AD, compared to HS. No metabolites changed significantly between SMC and
MCI, and FC did not show significant changes among groups (Table 2). Twelve metabolites
and 3 molar ratios were identified by PLS-DA as VIP with a score> 1.3 (Fig 3). ROC curves
(Fig 4) showed that the diagnostic accuracy of ALC was very good (AUC = 0.82) and that of
other acyl-carnitines, such as C12, C18:1 and C18:2, was good (AUC between 0.7 and 0.8), sug-
gesting that these metabolites could be proposed as potential biomarkers for the diagnosis of
AD.
Previous studies, evaluating the serum level of FC and several acyl-carnitines in subjects
with cognitive complaints, studied patients with AD or MCI [28, 29] or converters to MCI/AD
[28], but not subjects with SMC. These studies were performed by different methodological
approaches, therefore it is difficult to compare these results with that obtained in our study.
Mapstone et al. [28] used an ultraperformance liquid chromatography–electrospray ionization
quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOF-MS)-based data acquisition,
and least absolute shrinkage and selection operator (LASSO) analysis for untargeted metabolo-
mic profiling. They reported significant low levels of some acyl-carnitines such as C3 and
C16:1-OH in the converter group, before and after phenoconversion to MCI/AD, and in the
MCI/AD group. González-Domínguez et al. [29] used a capillary electrophoresis–mass spec-
trometry (CE-MS) approach for signal acquisition and a complex data processing, including a
PLS-DA analysis, for untargeted metabolomic profiling. They found in patients with AD and
Table 2. (Continued)
Metabolites Group* ANOVA Significant pairwise comparisons
AD MCI SMC HS F (3,
109)
p
value
Tetradecadienoyl- (C14:2) 0.039
(0.015)
0.042
(0.018)
0.035
(0.014)
0.038
(0.011)
0.798 0.498 n.a.
3-hydroxytetradecanoyl-
(C14-OH)
0.010
(0.005)
0.008
(0.003)
0.009
(0.003)
0.009
(0.003)
1.699 0.172 n.a.
Palmitoyl- (C16) 0.101
(0.043)
0.165
(0.085)
0.132
(0.057)
0.120
(0.062)
3.548 0.017 AD vs MCI
Hexadecenoyl- (C16:1) 0.027
(0.008)
0.027
(0.007)
0.025
(0.005)
0.034
(0.010)
7.462 <0.001 AD vs HS; SMC vs HS; MCI vs HS
3-hydroxyhexadecanoyl-
(C16-OH)
0.007
(0.003)
0.007
(0.002)
0.007
(0.003)
0.007
(0.004)
0.440 0.725 n.a.
3-hydroxyhexadecenoyl-
(C16:1-OH)
0.008
(0.003)
0.006
(0.003)
0.006
(0.004)
0.007
(0.003)
1.308 0.276 n.a.
Stearoyl- (C18) 0.043
(0.011)
0.044
(0.011)
0.045
(0.011)
0.056
(0.016)
5.275 0.002 AD vs HS, SMC vs HS, MCI vs HS
Oleyl- (C18:1) 0.105
(0.031)
0.109
(0.025)
0.116
(0.031)
0.135
(0.039)
5.016 0.003 AD vs HS; MCI vs HS
Linoleyl- (C18:2) 0.033
(0.008)
0.036
(0.009)
0.038
(0.010)
0.042
(0.012)
2.700 0.049 AD vs HS
3-hydroxyoctadecanoyl-
(C18-OH)
0.007
(0.004)
0.007
(0.003)
0.006
(0.003)
0.009
(0.004)
3.004 0.034 SMC vs HS
3-hydroxyoctadecenoyl-
(C18:1-OH)
0.009
(0.004)
0.007
(0.003)
0.007
(0.003)
0.009
(0.003)
2.842 0.041 n.s.
AD, Alzheimer disease; MCI, mild cognitive impairment; SMC, subjective memory complaint; HS, healthy subjects; n.a., not applicable; n.s., not
significant; * data are means (standard deviation).
doi:10.1371/journal.pone.0155694.t002
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in subjects with MCI a significant decrease of FC and C5, and a significant increase of C8, C10
and C10:1. In older studies, Rubio et al. [30] reported significantly lower levels of plasma FC in
AD patients, while plasma acyl-carnitines and cerebrospinal fluid FC and acyl-carnitines were
within normal range. Makar et al. [31] reported reduced concentration of “total” carnitine (FC
plus acid-soluble carnitine esters) in several brain regions of AD patients, but such reduction
was not significant. A part from the diversity of methodological approaches, other possible
explanations of discrepant results might be the different number and characteristic of exam-
ined subjects, and the complex, multifactorial and multi-genetic nature of AD. Anyway, sup-
porting our findings, González-Domínguez et al. [32] demonstrated the deficit of several acyl-
carnitines, including ALC, in the brain (hippocampus and cerebral cortex) of APP/PS1 trans-
genic mouse model of AD.
The deficit of acyl-carnitines suggests a perturbed transport of fatty acids into the mitochon-
dria for beta-oxidation, as well as an altered energy metabolism. This hypothesis is in line with
the results of transcriptomic study showing a significant decrease in the activity of carnitine
shuttle in AD patients [33]. The deficit of carnitine shuttle might contribute to mitochondrial
dysfunctions supposed to be responsible for many neurodegenerative diseases including AD
[34]. The decreased serum levels of some acyl-carnitines found in MCI subjects might indi-
rectly signal an impending progression of dementia and might be used as biomarkers of pheno-
type conversion fromMCI to AD.
ALC is a small, water-soluble and easily transportable compound, found naturally in the
body and in small amounts in some foods. The synthesis of ALC and other acyl-carnitines
occurs inside the mitochondria from acylation of free hydroxyl group of L-carnitine (trimethy-
lamino-β-hydroxybutyrate) by the enzymes carnitine-acyltransferases, which catalyzes the
exchange of acyl groups between carnitine and coenzyme A. These enzymes include carnitine
Fig 1. Score plots for the PLS-DAmodel discriminating the 4 groups of subjects. Plots of the first two
(A) and first three (B) components that explain, respectively, the 52% and the 56.3% of model variance. AD
(red) samples were well separated from HS (light blue), while MCI (blue) and SMC (green) clustered in an
intermediate zone.
doi:10.1371/journal.pone.0155694.g001
Fig 2. Important features identified by PLS-DA. Twelve metabolites and 3 molar ratios show a VIP
score > 1.3.The colored boxes indicate the relative concentrations of the corresponding metabolite or the
relative value of ratios in each group.
doi:10.1371/journal.pone.0155694.g002
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acetyltransferase (CAT), carnitine octanoyltransferase (COT), and carnitine palmitoyltransfer-
ase (CPT) I and II, with substrate preferences for short chain, medium chain and long chain,
Fig 3. Serum levels of acyl-carnitines classified as VIP by PLS-DA. Box-plots showmedian (horizontal line in the box), 25th and 75th
percentiles (edges of box), maximum and minimum values (whiskers) and outliers (°,*) of acyl-carnitines concentrations (μmol/L) in the 4
groups of subjects. AD, Alzheimer’s disease; MCI, mild cognitive impairment; SMC subjective memory complaint; HS, healthy subjects;
(†) Significantly different from HS groups (see Table 2 for details).
doi:10.1371/journal.pone.0155694.g003
Fig 4. ROC curves of selected acyl-carnitines. The plots show the optimal value of cutoff (•), the value of full AUC with the 95% confidence intervals and
the best delimitation of AUC (black solid line) for each metabolite.
doi:10.1371/journal.pone.0155694.g004
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respectively [35]. CPT-I (located in the inner side of the outer mitochondrial membrane) and
CPT-II (in the inner leaflet of the inner mitochondrial matrix) are crucial for the β-oxidation
of fatty acids in the mitochondria, by facilitating their transport across the mitochondrial
membranes [36, 37]. CAT may be involved in the transport of acetyl-CoA across intracellular
membranes, in maintaining the acetyl-CoA:CoA balance, and in the excretion of excess or
harmful acyl molecules as acyl-carnitines [37, 38].
ALC has many different functions in the body. Because of its ability to go through the
brain-blood-barrier freely, it could help fatty acid to enter into mitochondria and improve the
brain’s energy metabolism. In addition, ALC could facilitate elimination of oxidative products,
provides acetyl groups for acetylcholine synthesis, stimulates membrane phospholipid synthe-
sis, exerts anti-apoptotic functions, modulates gene expression and neurotrophic factors pro-
duction, and protects from excitotoxicity [8, 39–42]. All such functions would explain why its
reduced levels may predispose to AD and may contribute to neurodegeneration underlining
the disease.
ALC may be of benefit in treating several neurological disorders, including AD, depression
in the elderly, HIV infection, diabetic neuropathies, peripheral neuropathic pain, brain ische-
mia, and cognitive impairment due to alcoholism [8, 43, 44]. However, despite its use in clinical
studies, little is known about its metabolism in normal aging and in subjects with different
degree of cognitive complaints. Kalaria and Harik [45] found a 25% to 40% decrease in CAT
activity in several brain regions and in cerebral microvessels of patients with AD. Makar et al.
[31] similarly reported a significant reduction of CAT activity in the cerebellum of AD patients.
Based on the essential role of carnitine to transport fatty acids across the inner mitochondrial
membrane for fatty acid oxidation, it is conceivable that the significant and progressive
decrease of either short-, medium- and long-chain acylcarnitines in SMC, MCI and AD com-
pared to HS may reflect a reduction in the activity of CAT, COT and CPT. It is likely that the
deficiency of these enzymes, in particular COT and CPT I, could have a significant effect on
energy production and could impair the mitochondrial functions. However, Perry et al. [46]
described normal CAT activity in amygdaloid and caudate nuclei of AD patients, and Maurer
et al. [47] reported normal activity of CPT, COT and CAT in several AD brain regions. Once
again, differences in methods and examined populations, and the complexity of AD might
explain the discrepant results. In effect, increasing evidences suggest that AD is a heteroge-
neous disorder that includes several subtypes with different pathogenic mechanisms and pro-
gression [48, 49].
Anyway, several studies suggested a beneficial effect of ALC on cognition and behavior in
aging and AD subjects [9–11]. The possible mechanisms of ALC action in ADmay involve
restoring of cell membranes, as well as synaptic function, enhancing cholinergic activity, restor-
ing brain energy, protecting against toxins, and exerting neurotrophic effects via stimulating
NGF and acetylation of proteins [8, 39, 40]. However, later, larger studies have not supported
these findings [12, 13]. In a recent meta-analysis including sixteen trials, Hudson and Tabet [14]
noted that early and later studies differed widely in methodology and assessment tools used, and
were therefore difficult to compare [14]. Anyway, the results of meta-analysis showed a statisti-
cally significant treatment effects in favor of ALC for clinical global impression at 12 and 24
weeks, and for MMSE at 24 weeks [14]. Similarly, another meta-analysis found significant treat-
ment effects of ALC for clinical global impression and for several psychometric tests [50].
Conclusion
The results of this study suggest that serum ALC and other acyl-carnitine concentrations
decrease along the continuum from HS through SMC and MCI subjects, up to patients with
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AD, and that the metabolism of some acyl-carnitines is finely connected among them. Further-
more, the reduced level of ALC in subjects with cognitive complaints could explain the
reported salutary effect of ALC administration in patients with AD. We suggest that the serum
levels of ALC and other acyl-carnitines could help to identify the patients before the phenotype
conversion to AD and the patients who would benefit from the treatment with ALC. However,
further validation on a larger number of samples in a longitudinal study is needed before appli-
cation to clinical practice.
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